Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for Mimedx (MDXG) over the last 15 years, with Q3 2025 value amounting to $4.4 million.

  • Mimedx's Other Accumulated Expenses rose 7047.47% to $4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.4 million, marking a year-over-year increase of 7047.47%. This contributed to the annual value of $4.5 million for FY2024, which is 5573.6% up from last year.
  • Mimedx's Other Accumulated Expenses amounted to $4.4 million in Q3 2025, which was up 7047.47% from $3.4 million recorded in Q2 2025.
  • In the past 5 years, Mimedx's Other Accumulated Expenses registered a high of $4.5 million during Q4 2024, and its lowest value of $1.6 million during Q1 2022.
  • For the 5-year period, Mimedx's Other Accumulated Expenses averaged around $2.5 million, with its median value being $2.0 million (2022).
  • In the last 5 years, Mimedx's Other Accumulated Expenses plummeted by 3141.56% in 2021 and then surged by 12692.31% in 2024.
  • Over the past 5 years, Mimedx's Other Accumulated Expenses (Quarter) stood at $1.6 million in 2021, then increased by 17.19% to $1.8 million in 2022, then soared by 57.8% to $2.9 million in 2023, then surged by 55.74% to $4.5 million in 2024, then fell by 2.0% to $4.4 million in 2025.
  • Its Other Accumulated Expenses stands at $4.4 million for Q3 2025, versus $3.4 million for Q2 2025 and $4.4 million for Q1 2025.